Loading…
logo
Jakavi 20 mg Tablet
common image
prescriptionPrescription Required

Jakavi 20 mg Tablet

10 Tablets in 1 Strip

wishlist
46408.98
discount
24% OFF
You save ₹ 14958.02

(Inclusive of all taxes)

Novartis Healthcare Pvt Ltd
Ruxolitinib 20 mg

Introduction of Jakavi 20 mg Tablet

Jakavi 20 mg Tablet is a prescription medication used to treat certain types of blood disorders. Jakavi 20 mg tablet is specifically used to treat adults with certain types of myelofibrosis (a type of bone marrow disorder) and polycythemia vera (a blood disorder characterized by an overproduction of red blood cells). A blood cell count must be performed before initiating therapy with Jakavi. Jakavi 20 mg is not recommended for use in patients under 12 years of age safety and efficacy are not established.


Uses of Jakavi 20 mg Tablet

Polycythemia Vera: Jakavi 20 mg is used in the treatment of polycythemia vera is a rare blood disorder in which the body produces too many red blood cells. The excess red blood cells can cause the blood to become thick and sticky, making it harder to flow through the vessels. This can lead to a number of complications, including an increased risk of blood clots that can cause a heart attack or stroke.

Chronic idiopathic myelofibrosis: Jakavi 20 mg tablet is used in the treatment of chronic idiopathic myelofibrosis (also called primary myelofibrosis) is a type of bone marrow disease in which the bone marrow is replaced by scar tissue, resulting in a decrease in the production of blood cells. The scar tissue can also lead to the accumulation of excess fluid in the abdomen (ascites) and the accumulation of fat cells in the liver and spleen.


Benefits of Jakavi 20 mg Tablet

Jakavi Tablet can be effective in reducing symptoms associated with myelofibrosis, such as fatigue, enlarged spleen, and uncontrolled bleeding.

Jakavi 20 mg tablet may improve the overall quality of life and reduce the symptoms of myelofibrosis.

Jakavi has been shown to reduce bone marrow fibrosis (scarring) in those with myelofibrosis.

Jakavi 20 mg prevent cancer in those with myelofibrosis and help to prevent the progression of myelofibrosis to acute myeloid leukaemia (AML).


Side Effects of Jakavi 20 mg Tablet

Like all medication, Jakavi 20 mg may cause some side effects. If you experience any of these side effects contact your doctor as soon as possible. Your doctor may be able to suggest ways to manage or reduce the severity of these side effects.


Most Common Side Effects of Jakavi 20 mg Tablet

  • Headache, dizziness
  • Weight gain
  • High blood pressure
  • High cholesterol
  • Flatulence
  • Abnormal liver function tests
  • Difficulty in breathing
  • Constipation


Common Side Effects of Jakavi 20 mg Tablet

  • Decrease in red blood cells
  • Infection


How to Use Jakavi 20 mg Tablet?

Jakavi 20 mg tablet may be taken with or without food. Take it at the same time each day. Swallow the tablet whole with a full glass of water. Do not crush, chew, or open the tablet. If you forget to take a dose, make up for it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.


How Jakavi 20 mg Tablet Works?

Jakavi belongs to the class of drugs known as Janus kinase inhibitors (JAK). The action of Jakavi 20 mg is based on inhibiting the activity of certain proteins called JAKs, which play a role in signalling pathways that regulate the production of certain proteins in the body. By inhibiting these proteins, Jakavi may help reduce inflammation and improve symptoms in certain diseases such as myelofibrosis and polycythemia vera.


Safety Advices Jakavi 20 mg Tablet

pregnancy
Pregnancy
Unsafe

Use of Jakavi 20 mg tablet may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Jakavi 20 mg during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.

breastfeeding
Breastfeeding
Unsafe

It is not recommended to breastfeed while taking Jakavi. Jakavi 20 mg tablet may pass into breast milk and harm the infant. If you are breastfeeding and taking Jakavi Tablet, it is important to talk to your doctor about the possible risks and benefits of continuing to breastfeed. Your doctor will be able to help you make the best decision for you and your baby's health.

alcohol
Alcohol
Unsafe

It is not recommended to consume alcohol while taking Jakavi 20 mg. Alcohol may increase the risk of side effects or interfere with the effectiveness of the Jakavi Tablet. It is best to talk to your doctor or pharmacist before consuming alcohol while taking any medicine.

liver
Liver
Use with Caution

Jakavi Tablet should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Jakavi 20 mg and report any unusual symptoms or changes in liver function to their doctor. The dose of Jakavi may need to be adjusted in patients with liver disease.

driving
Driving
Unsafe

Jakavi 20 mg tablet may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Jakavi.

kidney
Kidney
Use with Caution

Jakavi 20 mg should be used with caution in patients with Kidney disease. It is important that patients with kidney disease closely monitor kidney function while taking Jakavi Tablet and report any unusual symptoms or changes in kidney function to their doctor. The dose of Jakavi may need to be adjusted in patients with kidney disease.


References

1. The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf

2.DailyMed is a website operated by the U.S. National Library of Medicine to publish up-to-date and accurate drug labels to healthcare providers and the general public. The contents of DailyMed are provided and updated daily by the U.S. Food and Drug Administration

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b
​3. The Central Drugs Standard Control Organisation is India's national regulatory body for cosmetics, pharmaceuticals and medical devices.

https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPrescribingInfo/8Ruxolitinib%20India%20.pdf  

4. This result comes from www.medsafe.govt.nz

https://www.medsafe.govt.nz/profs/datasheet/j/jakavitab.pdf 

. Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, Massachusetts, United States. It is one of the largest pharmaceutical companies in the world.

https://www.novartis.com/sg-en/sites/novartis_sg/files/Jakavi-Oct.SIN2020v1-app070622-pdf.pdf  


Vaccines

INDIA’S LARGEST SPECIALITY MEDICINES PLATFORM
Genuine Medicines

Genuine Medicines

Fast Delivery

Fast Delivery

Secure Payment

Secure Payment

Best prices & offers

Best prices & offers